NCT04302857 is a clinical trial of routine MRI in Intracranial Neoplasm, sponsored by Tim Wende.

Who is sponsoring NCT04302857?

NCT04302857 is sponsored by Tim Wende.

What drugs are being tested in NCT04302857?

Interventions in NCT04302857: routine MRI.

What condition does NCT04302857 study?

NCT04302857 studies Intracranial Neoplasm.

Is NCT04302857 still recruiting?

NCT04302857 is currently completed. Last updated 10 June 2022.

Last reviewed 2022-06-10 · How we verify

NCT04302857

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tractography Pilot Study Leipzig

Completed Last updated 10 June 2022

What this trial tests

trial testing routine MRI in Intracranial Neoplasm in 20 participants. Completed in 31 December 2021.

Timeline

1 January 2020

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Tim Wende
Status	Completed
Study type	OBSERVATIONAL
Enrollment	20
Start date	1 January 2020
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across Germany

Drugs / interventions tested

routine MRI

Conditions studied

Intracranial Neoplasm — all drugs for Intracranial Neoplasm →

Sponsor

Tim Wende

Who can join

Adults 18 to 75, any sex, with Intracranial Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this pilot study participants will undergo routine magnetic resonance imaging and routine neurosurgical care. By prospectively collecting data from both MRI and patient records we want to investigate biomarkers derived from tractography and diffusion tensor imaging to predict rehabilitation potential.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Assessment of a Reliable Fractional Anisotropy Cutoff in Tractography of the Corticospinal Tract for Neurosurgical Patients.
Wende T, Kasper J, Wilhelmy F, Dietel E, et al · · 2021 · cited 10× · PMID 34065682 · DOI 10.3390/brainsci11050650
Preserved White Matter Integrity and Recovery After Brain Tumor Surgery: A Prospective Pilot Study on the Frontal Aslant Tract.
Wende T, Hoffmann A, Scherlach C, Kasper J, et al · · 2023 · cited 1× · PMID 37646398 · DOI 10.1089/brain.2023.0033

Verify or expand the search:

Other recruiting trials for Intracranial Neoplasm

Currently open trials in the same condition.

NCT06474533 — Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm · recruiting
NCT05891002 — Accuracy of Robotically Assisted Cranial Biopsies · recruiting
NCT04278118 — Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04302857 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tim Wende
Last refreshed: 10 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04302857.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing